New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 19, 2012
07:32 EDTHALO, VPHMViroPharma, Halozyme announce initiation of Phase 2b dose to evaluate Cinryze
ViroPharma (VPHM) and Halozyme (HALO) announced that ViroPharma has initiated its Phase 2b double blind, multicenter, dose ranging study to evaluate the safety and efficacy of subcutaneous administration of Cinryze in combination with Halozyme's Enhanze technology in adolescents and adults with hereditary angioedema for prevention of HAE attacks. This double blind, cross-over, dose ranging study will be conducted in approximately 40 adolescent and adult subjects in the U.S. and Europe. The primary efficacy endpoint is the normalized number of angioedema attacks recorded during each treatment period. In addition, several secondary endpoints will be assessed, including attack severity, quality of life parameters using a novel angioedema tool, and number of angioedema attacks requiring acute treatment.
News For VPHM;HALO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 24, 2015
08:31 EDTHALOHalozyme names Michael LaBarre chief scientific officer
Halozyme named Michael J. LaBarre, Ph.D. as chief scientific officer, succeeding Dr. Michael Shepard, who was appointed a Research Fellow for the company. "Mike has deep experience characterizing early stage assets, making him an ideal leader for our research organization as we invest further in our promising pipeline," said Dr. Helen Torley, president and chief executive officer. "We have a full agenda for the second half of 2015 as we broaden the study of our investigational new drug PEGPH20 in multiple tumor types and prepare for our pivotal phase 3 study in pancreatic cancer patients. I am pleased to have a proven leader of Mike's caliber to guide our research efforts as we invest for future growth."

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use